AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25001524
Drug: Cabazitaxel 25
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25 mg/m² i.v. Q3W plus oral prednisone/prednisolone 10 mg daily
Trial: 25002028
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CDK 4/6 inhibitors and PI3K inhibitors
Trial: 25002028
Drug: Single-agent PI3K
RxNorm normalized name: Pi3k.delta.-in-2
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent PI3K inhibitors
Trial: 25002028
Drug: PI3K inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PI3K inhibitor BYL719
Trial: 25002028
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PI3K and CDK 4/6 inhibitors
Trial: 25003311
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery system; subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing.
Trial: 25003359
Drug: Fingolimod (FTY720,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (FTY720, Gilenya), 0.5 mg, orally for 3 consecutive days
Trial: 25005255
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus trastuzumab with chemotherapy
Trial: 25005444
Drug: Desmopressin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.4 μg/kg IV
Trial: 25007130
Drug: AZD8931 ([(14)C]-AZD8931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 ([(14)C]-AZD8931) administered orally or intravenously; dosage not specified; single doses.
Trial: 25007130
Drug: AZD8931 metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 metabolism in rats; specific metabolic pathways not detailed.
Trial: 25007130
Drug: AZD8931 metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 metabolism in dogs; specific metabolic pathways not detailed.
Trial: 25007130
Drug: AZD8931 metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 metabolism in humans; specific metabolic pathways not detailed.
Trial: 25007944
Drug: Imatinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 200 mg/day for 6 months
Trial: 25008856
Drug: Provided diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided diet containing 6-cup equivalents (1046 g/d) of vegetables and fruit (8 wk, phase 2)
Trial: 25008917
Drug: HIV-1 gp140
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 gp140 linked to HSP70 administered vaginally
Trial: 25009010
Drug: AKT inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKT inhibitor treatment during the fourth line of therapy
Trial: 25009013
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with cetuximab, paclitaxel, and carboplatin
Trial: 25009013
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with cetuximab, paclitaxel, and carboplatin followed by CRT
Trial: 25009371
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies with albumin dialysis
Trial: 25010745
Drug: Magnesium at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium at 2.5 mmol/l
Trial: 25010745
Drug: Magnesium at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium at 1 mmol/l
Trial: 25011615
Drug: Epoetin zeta
RxNorm normalized name: Epoetin zeta
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin zeta (median dose 30,000 IU/week)
Trial: 25011656
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg linezolid intravenously twice a day
Trial: 25012994
Drug: Birth control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth control pill users (females)
Trial: 25012994
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy users (females)
Trial: 25015089
Drug: Capecitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1250 mg/m²) single-dose 2-3 hours before surgery
Trial: 25015089
Drug: Lapatinib (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1250 mg) daily for 2-5 doses, last dose 2-3 hours before surgery
Trial: 25015202
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation with weekly paclitaxel (60 mg/m² administered once weekly for 5 weeks during radiation therapy)
Trial: 25015413
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g oral glucose tolerance test (OGTT) using IADPSG criteria
Trial: 25015413
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g glucose challenge test (GCT)
Trial: 25015413
Drug: Standardized routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized routine care protocol for diabetes and GDM treatment
Trial: 25016003
Drug: Imexon (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imexon (1000 mg/m² IV daily for 5 days in 21-day cycles)
Trial: 25016127
Drug: Intravenous hematin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hematin
Trial: 25016368
Drug: Obstructive Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstructive Sleep Apnea (OSA) treatment according to national guidelines
Trial: 25016924
Drug: Ramucirumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (8 mg/kg intravenously every 2 weeks)
Trial: 25018910
Drug: Bone marrow-derived,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived, culture-expanded allogeneic mesenchymal stem cells administered into the suprarenal aorta after reflow.
Trial: 25019562
Drug: T1 time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1 time 12 minutes after contrast material injection
Trial: 25019562
Drug: T1 time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1 time 25 minutes after contrast material injection
Trial: 25020262
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite in a continual infusion of 750μg/24h for 6 days
Trial: 25022285
Drug: Rosuvastatin 5-20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5-20 mg/day
Trial: 25022828
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg (Clop-75)
Trial: 25022828
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg (Pras-5)
Trial: 25022828
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg (Pras-10)
Trial: 25022935
Drug: Omentin-1 levels
RxNorm normalized name: benztropine mesylate 1 MG/ML [Cogentin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omentin-1 levels in AMI patients at baseline: 18.73 ± 3.66 ng/ml
Trial: 25022935
Drug: Chemerin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemerin levels in AMI patients at baseline: 263.37 ± 73.32 ng/ml
Trial: 25023888
Drug: Liraglutide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (50 μg/kg; i.p.)
Trial: 25023888
Drug: Imipramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (10 mg/kg; i.p.)
Trial: 25023888
Drug: Liraglutide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (50 μg/kg; i.p., daily for 3 weeks)
Trial: 25023888
Drug: Olanzapine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (0.5 mg/kg; p.o. for 8-9 weeks)
Trial: 25023926
Drug: Time controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time controls (no diet therapy)
Trial: 25024303
Drug: DA-EPOCH-R (infusional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-EPOCH-R (infusional dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine, prednisone, and rituximab)
Trial: 25025963
Drug: Olaparib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (up to 400 mg bid) plus liposomal doxorubicin (PLD) 40 mg m(-2)
Trial: 25025963
Drug: Olaparib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (up to 400 mg bid) plus PLD 40 mg m(-2)
Trial: 25028353
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficiency (serum 25OHD < 50 nmol/L)
Trial: 25028353
Drug: Sufficient Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient Vitamin D (serum 25OHD ≥ 50 nmol/L)
Trial: 25029335
Drug: JAK inhibitors
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK inhibitors on lymphocytes from affected children
Trial: 25030840
Drug: Oral QLT091001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QLT091001 (10-40 mg/m(2) per day for 7 days)
Trial: 25032816
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment for 12 weeks
Trial: 25034977
Drug: plm60-s at
RxNorm normalized name: crospovidone (15 mpa.s at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plm60-s at 10 mg/m(2)
Trial: 25034977
Drug: plm60-s at
RxNorm normalized name: crospovidone (15 mpa.s at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plm60-s at 18 mg/m(2)
Trial: 25034977
Drug: c-MI at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c-MI at 10 mg/m(2)
Trial: 25037041
Drug: Maternal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal vitamin D insufficiency (<32 ng/mL)
Trial: 25037684
Drug: IV trebananib
RxNorm normalized name: Trebananib
DrugBank: Trebananib (DB12056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV trebananib 15 mg/kg QW plus paclitaxel 175 mg/m(2) Q3W and carboplatin 6 mg/mL · min Q3W followed by trebananib 15 mg/kg QW monotherapy for 18 months
Trial: 25037863
Drug: Continuous daily
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous daily oral afatinib (30 mg starting dose, escalation to 50 mg) combined with intravenous pemetrexed (500 mg/m2)
Trial: 25037863
Drug: Pulsed-dose daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed-dose daily oral afatinib (50 mg starting dose, escalation to 70 mg) combined with intravenous pemetrexed (500 mg/m2)
Trial: 25037863
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing schedules (SA and SB)
Trial: 25038354
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg and weight-based ribavirin for 12 weeks
Trial: 25038354
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg and weight-based ribavirin for 24 weeks
Trial: 25038354
Drug: Sofosbuvir and
RxNorm normalized name: sofosbuvir and ledipasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir and ribavirin treatment
Trial: 25038824
Drug: Cetuximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (500 mg/m2, 2 h) + Irinotecan (125 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Trial: 25038824
Drug: Cetuximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (500 mg/m2, 2 h) + Irinotecan (165 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Trial: 25038824
Drug: Cetuximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (500 mg/m2, 2 h) + Irinotecan (95 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Trial: 25040144
Drug: Serum 1,3-beta-d-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 1,3-beta-d-glucan (BDG) testing prior to initiation of antifungal (AF) treatment
Trial: 25040462
Drug: venlafaxine 150
RxNorm normalized name: venlafaxine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine 150 mg/day for 6 weeks
Trial: 25042202
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg per day plus R-CHOP
Trial: 25042797
Drug: Peginterferon lambda-1a
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda-1a (Lambda) at 120, 180, and 240 μg with ribavirin
Trial: 25042797
Drug: Peginterferon lambda-1a
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda-1a (Lambda) at 240 μg with ribavirin
Trial: 25042797
Drug: Peginterferon lambda-1a
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda-1a (Lambda) at all doses with ribavirin
Trial: 25043069
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg loading dose (LD)
Trial: 25043069
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg maintenance dose (MD)
Trial: 25043069
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg loading dose (LD) in CYP2C19 loss-of-function carriers
Trial: 25043069
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg maintenance dose (MD) in CYP2C19 loss-of-function carriers
Trial: 25043069
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg loading dose (LD) in CYP2C19 non-carriers
Trial: 25043069
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg maintenance dose (MD) in CYP2C19 non-carriers
Trial: 25043869
Drug: suPAR levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR levels in patient groups (initial level 18.8 ng/mL, range 6.8-30.1 ng/mL)
Trial: 25043869
Drug: suPAR levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR levels in control group (initial level 6.0 ng/mL, range 3.7-10.8 ng/mL)
Trial: 25046246
Drug: Combined pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacotherapy and psychotherapy (cognitive behavioral therapy or psychoeducation)
Trial: 25047123
Drug: Lenvatinib (E7080)
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib (E7080) administered twice daily in 3-week cycles; 2 weeks of treatment followed by 1 week of rest.
Trial: 25047747
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy plus bevacizumab
Trial: 25047979
Drug: Pomalidomide (0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (0.5mg daily) with prednisone (for the first 3 cycles)
Trial: 25049247
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg posaconazole once daily
Trial: 25049247
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg posaconazole once daily
Trial: 25049249
Drug: Artemisinin (ART)-based
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin (ART)-based combination therapies (ACTs)
Trial: 25052051
Drug: Obatoclax mesylate
RxNorm normalized name: mesylate
DrugBank: Obatoclax (DB12191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obatoclax mesylate 60 mg intravenous over 24 hours every 2 weeks
Trial: 25052451
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² on days 1 and 8 and cisplatin 70 mg/m² on day 1 every 21 days with lenalidomide 10 mg daily on days 1-14 (phase Ib).
Trial: 25052451
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and cisplatin (GCL) regimen without lenalidomide (control group not explicitly mentioned but implied as standard treatment).
Trial: 25052720
Drug: IMRT-HT (Intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT-HT (Intensity Modulated Radiation Therapy delivered by helical tomotherapy)
Trial: 25056691
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids (EAAs) ingestion (13 g; 2.4 g of Leu)
Trial: 25057177
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg i.v. weekly added to rituximab (375 mg/m2 i.v. day 1) and cladribine (5 mg/m2/day i.v. days 1-5 of a 28-day cycle)
Trial: 25057177
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg i.v. weekly added to rituximab and cladribine
Trial: 25057265
Drug: Nonselective nonsteroidal
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs)
Trial: 25057276
Drug: pterostilbene 125 mg
DrugBank: Pterostilbene (DB17939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pterostilbene 125 mg twice daily
Trial: 25057276
Drug: pterostilbene 50 mg
DrugBank: Pterostilbene (DB17939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pterostilbene 50 mg twice daily
Trial: 25057276
Drug: pterostilbene 50 mg
DrugBank: Pterostilbene (DB17939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pterostilbene 50 mg + grape extract (GE) 100 mg twice daily
Trial: 25057276
Drug: high dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose pterostilbene
Trial: 25058217
Drug: Nonmyeloablative allogeneic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) with alemtuzumab (1 mg/kg), total-body irradiation (300 cGy), sirolimus, and filgrastim mobilized peripheral blood stem cells (5.5-31.7 × 10(6) cells/kg)
Trial: 25058267
Drug: Peritoneal lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal lactate value greater than 9.1 mmol/L
Trial: 25062507
Drug: Dextromethorphan/quinidine (DM/Q)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan/quinidine (DM/Q) 30/30 mg twice daily
Trial: 25062770
Drug: Decitabine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine 0.1 or 0.2 mg/kg three times weekly for 2 weeks, Panobinostat 10, 20, or 30 mg every 96 h, Temozolomide 150 mg/m(2)/day on days 9-13 (increased to 200 mg/m(2)/day in cycle 2 if no neutropenia or thrombocytopenia)
Trial: 25062770
Drug: Maintenance protocol
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance protocol with weekly panobinostat and thrice-weekly decitabine until tumor progression, unacceptable toxicity, or withdrawal of consent
Trial: 25064094
Drug: Pirfenidone (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (1200 mg/day) for 24 months
Trial: 25067985
Drug: Cactus fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cactus fiber (2 tablets thrice daily with main meals)
Trial: 25067985
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets thrice daily with main meals)
Trial: 25069627
Drug: Opioids and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids and/or acetaminophen (oral oxycodone and/or acetaminophen)
Trial: 25069627
Drug: Opioids (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids (total daily consumption)
Trial: 25069627
Drug: Analgesic administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic administration methods
Trial: 25070153
Drug: Oral nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicorandil (15 mg/d, nicorandil group)
Trial: 25070153
Drug: Oral nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicorandil
Trial: 25074036
Drug: Gemcitabine (800-1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (800-1,000 mg/m² on days 1, 8, and 15, then every 3-4 weeks)
Trial: 25074036
Drug: S-1 (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (40-80 mg/m²/day on days 1-28, then every 3-6 weeks)